News

We Spent a Year Investigating How the FDA Let Risky Drugs Into the U.S. Market
Our investigation exposed a little-known practice inside the FDA that allowed more than 150 drugs or their ingredients into ...
Kraft Heinz removing all artificial dyes from US products by end of 2027
Kraft Heinz plans to remove all artificial dyes from its U.S. products by 2027 amid the Trump administration's push to remove ...
Kraft Heinz pulling certain artificial dyes from its US products in 2027
Kraft Heinz will be pulling certain artificial dyes from its U.S. products starting in 2027 and will no longer roll out new ...
Capricor Therapeutics' Becker Muscular Dystrophy Drug Gets Orphan Drug Designation in U.S.
Capricor Therapeutics has received an orphan drug designation for its drug aimed at potentially treating Becker Muscular Dystrophy. The biotechnology company said Tuesday that the Food and Drug ...
Futurism on MSN3d
The FDA Is Already Outsourcing Drug and Food Analysis to Error-Plagued AI Chatbot
The FDA plans to "unleash AI" on new drug evaluations in order to "radically increase efficiency in the review process." ...
Pharmabiz3h
Celltrion announces US FDA approval of additional presentation of Steqeyma, expanding dosing options for paediatric patients
Incheon, South Korea Tuesday, June 17, 2025, 16:00 Hrs [IST] ...
US FDA extends review of KalVista's swelling disorder drug due to heavy workload
KalVista Pharmaceuticals' said on Friday that the U.S. Food and Drug Administration had extended the review of its drug for a ...
US FDA puts on hold Rein Therapeutics' lung disease drug trial
Rein Therapeutics has paused patient enrollment and dosing in a mid-stage trial of its lung disease drug in the U.S. after ...
U.S. News & World Report3d
US FDA Extends Review of KalVista's Swelling Disorder Drug Due to Heavy Workload
US FDA Extends Review of KalVista's Swelling Disorder Drug Due to Heavy Workload By Puyaan Singh (Reuters) -KalVista Pharmaceuticals' said on Friday that the U.S. Food and Drug Administration had ...